Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction

Conclusions and Relevance: S100A12 rapidly identified patients with STEMI, more accurately than other cardiac biomarkers, especially within the first 2 h after symptom onset. The peak plasma S100A12 level was a strong predictor of 1-year prognosis after STEMI.PMID:34977174 | PMC:PMC8718434 | DOI:10.3389/fcvm.2021.747511
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research